An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants With DSM-5 Schizophrenia

The study design is a de-escalation of current atypical AP treatment to X/T at a maintenance dose of X/T established either at 100 mg xanomeline/20 mg trospium chloride BID (total daily dose 200 mg xanomeline/40 mg trospium chloride) or 125 mg xanomeline/30 mg trospium chloride BID (total daily dose 250 mg xanomeline/60 mg trospium chloride) based on participants' clinical response and/or tolerability. While the package insert for X/T provides guidance for clinicians on dosing, this study is designed to assess how transitioning will occur in the "real world" situation.

Study Overview

• Status: Not yet recruiting
• Conditions: Schizophrenia Disorders
• Intervention / Treatment: Drug: Xanomeline and Trospium Chloride; Drug: Xanomeline and Trospium Chloride

Detailed Description

This will be a 2-arm, multicenter, randomized, 8-week, open-label study to evaluate the safety and tolerability, as well as the efficacy, of transition in adult participants with schizophrenia in an outpatient setting from oral atypical AP treatment to X/T.

The study design is a de-escalation of current oral atypical AP therapy to a X/T via accelerated or slower transition from current treatment.

The study will consist of a Screening Phase of up to 14 days, a Pre-switch Baseline Visit, an 8 week open-label Treatment Phase, and a safety Follow-up/End of Study (EOS) Visit at 7+2 days following the last dose of X/T for participants who complete the Treatment Phase and those who prematurely discontinue from the study. Participants who prematurely discontinue from the study due to AEs or lack of efficacy will be encouraged to continue with study procedures even though they are no longer receiving study drug.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • California
    • Bellflower, California, United States, 90706
      • CenExel CIT LA
      • Contact: Phone Number: 866-478-8391
      • Contact: Gerald Maguire, M.D.
    • Garden Grove, California, United States, 92845
      • CenExel CNS - Garden Grove
      • Contact: Phone Number: 844-562-3232
      • Contact: David Walling, Ph.D.
    • Riverside, California, United States, 92506
      • Cenexel CIT IE
      • Contact: Phone Number: 866-478-8391
      • Contact: Evagelos Coskinas, M.D.
    • Torrance, California, United States, 90504
      • Cenexel Cns - Torrance
  • Florida
    • Hollywood, Florida, United States, 33024
      • Cenexel RCA
      • Contact: Phone Number: 954-919-7723
      • Contact: Edwin Gomez, M.D.
  • Maryland
    • Gaithersburg, Maryland, United States, 20877
      • CenExel CBH
      • Contact: Phone Number: 301-251-4702
      • Contact: Elia Acevedo-Diaz, M.D.
  • New Jersey
    • Marlton, New Jersey, United States, 08053
      • CenExel HRI Marlton

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Participant is aged 18 to 65 years, inclusive, at Screening.

2. Participant is capable of providing informed consent.

   1. A signed informed consent form (ICF) must be provided before any study assessments are performed.
   2. Participant must be fluent in English (oral and written) as the language of the ICF to consent. No translations will be permitted.
3. Participant has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (American Psychiatric Association 2013) criteria and confirmed by MINI for Schizophrenia and Psychotic Disorder Studies version 7.0.2.
4. Participant has not required psychiatric hospitalization, acute crisis intervention, or other increase in level of care due to symptom exacerbation within 12 weeks of Screening and is psychiatrically stable in the opinion of the Investigator.

5. PANSS Total Score of ≤80 at Screening and Baseline Visits.

   a. Score of ≤4 for the following core Positive Subscale items on PANSS: i. Item 2 (P2): Conceptual disorganization ii. Item 7 (P7): Hostility

6. CGI-S score of ≤4 at Screening and Baseline Visits.
7. Participant must be judged by the Investigator to be an appropriate candidate for transitioning from current oral AP medication due to safety or tolerability concerns and/or insufficient efficacy.

8. Participant is taking an oral AP and the AP regimen has been stable for at least 6 weeks prior to Screening. Participants are permitted to remain on non-prohibited (see Section 5.2, Exclusion Criterion #14, and Section 7.8) psychotropic medications (that are not secondary AP treatments) other than the primary pre-switch AP that have been part of their ongoing treatment regimen.

   1. For at least 6 weeks prior to Screening, the participant must be taking a single oral atypical AP medication at a dose and frequency consistent with the drug label. Low dose quetiapine (e.g., taken for sleep) taken in the 6 week prior to Screening is not exclusionary but must be discontinued by the Baseline Visit.

   2. Participant must be currently treated with one of the following selected atypical oral AP at the same dosing regimen at package insert specified dose range for schizophrenia for ≥6 weeks:

      • Risperidone
      • Paliperidone
      • Aripiprazole
      • Ziprasidone
      • Quetiapine
      • Lurasidone
      • Lumateperone
      • Brexpiprazole
      • Olanzapine No participants taking first-generation (typical) AP are to be included in the study.
9. In the opinion of the Investigator, it is clinically appropriate for the participant to discontinue current AP therapy and initiate treatment with X/T.
10. Participant is willing and able, in the opinion of the Investigator, to discontinue all secondary AP medications prior to Baseline visit.
11. BMI must be ≥18 and ≤40 kg/m2.
12. Participant resides in a stable living situation and is anticipated to remain in a stable living situation for the duration of study enrollment, in the opinion of the investigator.
13. Individuals of childbearing potential (IOCBP) must be willing and able to adhere to the contraception guidelines as defined in Appendix 1.

Exclusion Criteria:

1. Any primary DSM-5 disorder other than schizophrenia within 6 months before Screening (confirmed using MINI version 7.0.2 at Screening). Exclusionary disorders include, but are not limited to, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild mood dysphoria or anxiety are allowed as long as these symptoms are not the primary focus of treatment.

2. Participant has a history of moderate to severe alcohol use disorder or a substance (other than nicotine or caffeine) use disorder within the past 6 months or a positive urine drug screen (UDS) for a substance other than cannabis at Screening or Baseline.

   1. Participants with mild substance use disorder within the 6 months before Screening must be discussed and agreed upon with the Principal Investigator (PI) before they can be allowed into the study.
   2. Participants with positive UDS for cannabis are permitted to enroll in the study provided that the participants' pattern of use is not indicative of a substance use disorder.
   3. Urine toxicology screen positive for phencyclidine, amphetamines, opiates, cocaine, or alcohol (clinically significant alcohol use in the opinion of the Investigator).
3. History or presence of clinically significant cardiovascular (e.g., untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, gastrointestinal (GI, e.g., obstructive disorders [including conditions that may decrease GI motility, such as ulcerative colitis, intestinal atony, and myasthenia gravis], endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the participant or the validity of the study results.
4. Participant with cirrhosis, biliary duct abnormalities, and/or hepatobiliary carcinoma based on either medical history or liver function test results.
5. All grades of hepatic impairment (mild [Child-Pugh Class A], moderate [Child-Pugh Class B], and severe [Child-Pugh Class C]).
6. History or high risk of urinary retention or gastric retention.
7. History of narrow-angle glaucoma.
8. History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months.
9. Risk for suicidal behavior during the study as determined by the Investigator's clinical assessment. Non-suicidal self-injurious behavior is not exclusionary.
10. Clinically significant abnormal finding on the physical examination, medical history, or clinical laboratory results at Screening.
11. An eGFR of < 60 mL/min
12. Elevations in hepatic transaminases at screening ≥3× ULN for ALT and AST and/or bilirubin > 2× ULN, unless in the context of Gilbert's syndrome

13. History of unstable hypertension or tachycardia as evidenced by:

    1. Blood pressure of ≥160/100 mmHg (single seated measure) at screening
    2. Heart rate of ≥110 bpm (single seated measure) at Screening
14. Participant is receiving other psychotropic medications for psychiatric and neurological conditions with Anticholinergic Risk Scale (ARS) scores >1 (tricyclic antidepressants, paroxetine, antispasmodics, antihistamines with anticholinergic properties).

15. History of treatment resistance to schizophrenia medications defined as:

    1. Failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) within the past 12 months OR
    2. Has a history of having received clozapine
16. Participant is receiving a long-acting injectable AP.
17. Developmental disorder, intellectual disability, or autism spectrum disorder (by history), with the exception of participants diagnosed with autism at age <18 due to historic diagnostic criteria precluding schizophrenia diagnoses of minors (at discretion of Investigator).
18. Lifetime history of clinically significant head trauma.
19. Pregnant, breastfeeding, or less than 3 months postpartum.
20. Active biliary disease (e.g., symptomatic gallstones). Participants with other biliary histories are eligible and should be discussed with the Medical Monitor.

21. Participants with any of the following:

    1. History of bladder stones
    2. History of recurrent urinary tract infections
    3. For male participants, serum prostate-specific antigen >10 ng/mL at Screening
    4. For male participants ≥45 years of age, International Prostate Symptom Score (IPSS) of 5 (i.e., "almost always") on items 1, 3, 5, or 6
    5. For male participants ≥45 years of age, an IPSS ≥9 for the sum of items 1, 3, 5, and 6
22. In the opinion of the Investigator (and/or Sponsor), participant is unsuitable for enrollment in the study, or participant has any finding that, in the opinion of the Investigator (and/or Sponsor), may compromise the safety of the participant or affect their ability to adhere to the protocol visit schedule or fulfill visit requirements.
23. Participant has had psychiatric hospitalization(s) for more than 30 days (cumulative) within the 12 months before Screening.
24. Participant with prior exposure to X/T or who has a history of prior X/T intolerability (allergy/hypersensitivity).
25. Risk of violent or destructive behavior in the opinion of the Investigator.
26. Current involuntary hospitalization or incarceration.
27. Participation in another clinical study in which the participant received an experimental or investigational drug agent within 3 months prior to Screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: accelerated transition; accelerated transition arm will reduce the atypical AP treatment at a rate of 50% of the initial treatment over a 2-week period,	Drug: Xanomeline and Trospium Chloride; accelerated titration of Xanomeline and Trospium Chloride; Drug: Xanomeline and Trospium Chloride; slow titration of Xanomeline and Trospium Chloride
Other: slower transition; slower transition arm will reduce the atypical AP treatment at a rate of 25% of the initial treatment over a 4-week period	Drug: Xanomeline and Trospium Chloride; accelerated titration of Xanomeline and Trospium Chloride; Drug: Xanomeline and Trospium Chloride; slow titration of Xanomeline and Trospium Chloride

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
discontinuation rate of accelerated and slower switching of atypical antipsychotic (AP) treatment to xanomeline and trospium chloride (X/T)	To evaluate all-cause X/T discontinuation rate of accelerated and slower switching of atypical antipsychotic (AP) treatment to xanomeline and trospium chloride (X/T) over a period of 8 weeks	8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
evaluate the effectiveness of switching outpatients from standard atypical AP treatment to X/T	To evaluate the effectiveness of switching outpatients from standard atypical AP treatment to X/T over a period of 8 weeks	8 weeks
evaluate the safety and tolerability of X/T following switch from atypical AP	To evaluate the safety and tolerability of X/T following switch from atypical AP	8 weeks

Collaborators and Investigators

• Sponsor: Collaborative Neuroscience Research, LLC
• Collaborators: Bristol-Myers Squibb

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2025
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: March 31, 2025
• First Submitted That Met QC Criteria: April 10, 2025
• First Posted (Actual): April 11, 2025

Study Record Updates

• Last Update Posted (Actual): April 11, 2025
• Last Update Submitted That Met QC Criteria: April 10, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: Schizophrenia
• Additional Relevant MeSH Terms: Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Schizophrenia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Neurotransmitter Agents; Psychotropic Drugs; Urological Agents; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Cholinergic Agonists; Parasympatholytics; Parasympathomimetics; Muscarinic Agonists; Xanomeline; Trospium chloride
• Other Study ID Numbers: CN012-0079

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Deciding on what journals to submit data

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes